What drives us.
Founded for a medical revolution. Born from clinical innovation.
Antimicrobial resistance (AMR) is a global threat. At Delta G Avaris, we face this challenge with an approach born from clinical practice: phage therapy. Our goal is to save lives, restore quality of life, and secure the future of medicine.
- Location
- Hannover · Germany
- Focus
- Bacteriophage biology, personalized phage therapy
- Target Pathogens
- ESKAPE Pathogens
- Quality
- GMP-compliant processes in preparation
- Funding
- BSFZ · Research Allowance 2024 / 2026
A holistic, personalized approach against AMR.
Our goal is to combat antimicrobial resistance using a holistic, personalized phage therapy approach — spanning the full pipeline from analysis to application.
From pioneers to full-service provider.
Our founding team includes physicians who have already achieved successful results with phage therapy. We are working to bring this alternative to antibiotics into standard medical care — and to become the leading full-service provider for personalized phage therapy in the long term.
Combating ESKAPE pathogens.
Our mission is to make phage therapy globally accessible and integrate it into daily medical practice — through precise, industrially scaled, GMP-certified production and a reliable supply chain for the magistral treatment of ESKAPE pathogens.
Three principles that guide our work.
Scientific Excellence
We commit to the highest scientific standards in all areas of our research.
Transparency
Open communication and transparent presentation of our research activities are fundamental pillars of our work.
Responsibility
Responsible handling of scientific findings and compliance with all regulatory requirements.
The scale of the problem.
AMR threatens to undo decades of medical progress. Our approach uses phages — natural viruses that specifically target bacteria — offering new hope where antibiotics fail.
Antimicrobial resistance was associated with approximately 4.95 million deaths worldwide, including 1.27 million directly caused by resistant infections.
The Lancet (2022)Without countermeasures, AMR could cause up to 10 million deaths annually.
World Health Organization (WHO)In individual healing attempts, our medical team has achieved a success rate of over 80% — including bacterial load reduction and eradication.
Z Herz- Thorax- Gefäßchir (2025)Meet the team.
People working on bacteriophage research at Delta G Avaris.
Further professional information.
Scientific data, product information, and study documents are exclusively available to members of the medical profession in the restricted area.